Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kohei Yamauchi (Morioka, Japan), Yuka Oikawa, Nobuhito Sasaki, Miyuki Niisato, Yutaka Nakamura, Kohei Yamauchi. A phosphatidylinositol 3-kinase Inhibitor strongly suppressed pulmonary vascular remodeling in a murine model of allergic vasculitis. Eur Respir J 2015; 46: Suppl. 59, 1888

Member's Comments

No comment yet.

Related content which might interest you: Anti IL-17 with or without Rho kinase inhibitor in mice with chronic allergic pulmonary inflammation Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 NLRP3 inflammasome is activated via phosphoinositide 3-kinase δ pathway in Aspergillus fumigatus-induced allergic airway inflammation Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 Pre-clinical evaluation of a novel and selective PI3K δ/gamma inhibitor in pulmonary fibrosis Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Inhibitor effect of Janus kinase II in bleomycin-induced pulmonary fibrosis model Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Plant proteinase inhibitor from enterolobium contortisiliquum (EcTI) attenuates elastase-induced pulmonary inflammatory and remodeling alterations in mice Source: Annual Congress 2011 - Recent developments in COPD Year: 2011 Effects of broad spectrum tyrosin kinase inhibitor on pulmonary circulation homeostasis Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Activation of AMPK inhibits pulmonary arterial remodeling Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Phosphoinositide 3-kinase ? inhibitor suppresses interleukin-17 expression in a murine asthma model Source: Eur Respir J 2010; 36: 1448-1459 Year: 2010 LATE-BREAKING ABSTRACT: Anti-inflammatory effect of RP6557, a dual PI3K d/? inhibitor, in glucocorticoid insensitive human neutrophils from chronic obstructive pulmonary disease patients Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Metformin inhibits TGF-b-induced myofibroblast differentiation through AMPK activation Source: International Congress 2014 – Cell biology 2014 Year: 2014 BmTI-A: A serine protease inhibitor attenuates hyperresponsiveness in an experimental model of chronic allergic inflammation in Balb/c mice Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 Effect of anti-IL17 and/or Rho-kinase inhibitor treatments on vascular remodelling in an asthma model in mice Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 Selective TSC1 deletion in smooth muscle activates mTOR signaling and induces pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Phosphoinositide 3-kinase δ inhibitor suppresses IL-17 expression in a murine model of asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009 Hemodynamic and anti-remodelling effect of the Rho kinase inhibitor Y-27632 in the monocrotaline pulmonary arterial hypertension rat model Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016